ProImmune - Mastering Immunity | MHC pentamers, CD1d tetramers, custom peptide synthesis, immunoassays, T cell epitope discovery, HLA tissue typing, cellular analysis, ligand binding assays, immune response

Mastering Immunity

ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. Our unique innovative solutions for preclinical and clinical immunology research help you take your studies to success through responsive service and focused application support, saving you time and money and reducing risk.

Our Story     Our Clients

  

Request a Quote

Subscribe to Email Newsletters

 

USA/Canada Toll free: + 1 888 505 7765

All other countries: + 44 870 042 7279

enquiries@proimmune.com

Mastering Immunity Video Content

Dr. Wojciech Jankowski

FDA

"Non-clinical Assessments of Immunogenicity"

Dr. Daron Forman

Bristol-Myers Squibb

"The use of immunogenicity risk assessment tools for lead optimization of biologics"

Dr. Bartek Zuber

Swedish Orphan Biovitrum, Sweden

"Immunogenicity assessment for Affibody-Fc fusion therapeutics"

Dr. Timothy Hickling

Pfizer, Inc.

"Contribution of ex vivo assays to immunogenicity risk assessment"

Prof. Mark Exley

Agenus Inc., USA

"Phosphopeptide NeoAntigens for Tumor Immunity: Novel therapeutic options"

Prof. Christine Falk

Medizinische Hochschule Hannover, Germany

"Precision Medicine in Transplantation - immune monitoring for the discrimination of GVHD, rejection and CMV infection"

Dr. Bernard Maillère

CEA, France

“Comprehensive analysis of pre-existing T cells specific to therapeutic proteins in healthy donors”

Dr. Ethan Shevach

NIAID, NIH

"Tregs - ready for the clinic?"

Dr. Susan Kirshner

FDA

"Therapeutic Proteins: Route of exposure and immunogenicity risk"

Prof. Jean Rommelaere

DKFZ, Germany

“Use of oncolytic parvoviruses in the treatment of malignant gliomas: a viro-immunotherapeutic approach”

Prof. Paul Moss

University of Birmingham

“Direct visualisation of antigen-specific CD4+ T cells: insights from HLA class II tetramers”

Watch More Content

Products

Pro5® MHC Pentamers for T Cell detection

ProVE® Class I MHC Pentamer Libraries

ProT2® MHC Class II Tetramers

ProM2® MHC Class II Monomers

CD1d Tetramers for NKT Cell detection

ProMix™ Immunodominant Peptide Pools

thinkpeptides®: Custom Peptide Synthesis

Services (by application)

Immunogenicity in Drug Development

Immunotoxicology

Antigen Characterization

Immune Monitoring

 

Resources

Podcasts

Product Information Sheets

Free Resources & Downloads

Peptides Information Poster

Peptides eBook

Pentamer Catalog Pentamer Handbook Cancer Immunotherapy
Pro5® Pentamer catalog Pro5® Pentamer Handbook Opportunities in Cancer Immunotherapy

Latest News

HLA typing by Next Generation Sequencing (NGS)

Save the date: Join us for Mastering Immunity Europe 2018 in Oxford on 22 and 23 March 2018

Opportunities in Cancer Immunotherapy: download our  guide showing you how to capitalize on them with our products and services

 

Latest customer publications

Pro5® MHC Pentamers used in NIH study to investigate fatal brain stem pathology caused by antigen-specific CD8+ T cells in Malaria

Figure from: Swanson P.A. et al., PLOS Pathogens (2016) CD8+ T Cells Induce Fatal Brainstem Pathology during Cerebral Malaria via Luminal Antigen-Specific Engagement of Brain Vasculature
http://dx.doi.org/10.1371/journal.ppat.1006022